Usage Examples
- The BLA came back priority, so build the launch plan to a six-month goal date, not ten.
- Priority Review buys us nothing on the CMC package; the module 3 gaps still have to close before filing.
- We are holding a priority review voucher and deciding whether to spend it on this filing or sell it.
What is Priority Review?
Priority Review is an FDA marketing-application designation that shortens the agency's review-and-action target to six months, compressing the review clock only; it changes neither the evidence required nor the standard for approval.
Priority Review exists because FDA review capacity is finite and not every application deserves the same queue position. Congress and the agency needed a mechanism to move applications for serious conditions to the front without lowering the bar for approval. Priority Review does that by shortening the review-and-action target to six months, a commitment written into statute for the priority review voucher programmes.
Priority Review covers the review phase of a marketing application, the NDA or BLA already sitting with FDA. Priority Review does not reach into development: it shortens no trials, permits no surrogate endpoints, and changes no evidentiary requirement. Those levers belong to Fast Track, Breakthrough Therapy, and Accelerated Approval, three statutory programmes with their own criteria under section 506 of the FD&C Act.
Priority Review is assigned by FDA after the application arrives, not requested during development, so sponsors learn their goal date late and plan launch around it. Priority Review can also be purchased: a priority review voucher entitles its holder to priority review of a single human drug application. Either way FDA's filing decision, and with it acceptance for review, lands 60 days after receipt.
Not to be confused with
- Fast Track
- Fast Track is a development-stage designation resting on the potential to address unmet medical needs, requested and decided while trials are running. Priority Review is a review-stage designation applied to a finished application. Fast Track changes how a programme is run; Priority Review only changes how fast it is read.
- Breakthrough Therapy
- Breakthrough Therapy requires preliminary clinical evidence of substantial improvement over existing therapies on one or more clinically significant endpoints. Priority Review carries no clinical-evidence threshold of its own and is decided on the submitted application, not on interim data.
- Accelerated Approval
- Accelerated Approval changes what evidence can support approval, allowing a surrogate endpoint reasonably likely to predict clinical benefit. Priority Review changes nothing about the evidence, only the calendar. A product can be accelerated-approval eligible and still get a standard review clock.
- Priority Review Voucher
- a voucher is a transferable entitlement to priority review of a single human drug application, earned on a different product and often sold. Priority Review is the treatment; the voucher is the currency that buys it.
Priority Review imposes no separate submission content. The obligations that govern it are the ordinary application-review rules, and these are the anchors.
What you must do
- 1Plan the programme to a six-month review-and-action target, which is what priority status buys and the only thing it buys21 U.S.C. 360n(a)
- 2Track the regulatory review timeframe of 180 days from receipt, and re-baseline it whenever it is adjusted by mutual agreement or as the result of a major amendment21 CFR 314.100
- 3Build the 60-day filing decision into the submission calendar, because FDA determines within 60 days of receipt whether the application may be filed and sets the filing date at 60 days after receipt21 CFR 314.101
- 4Prepare a resubmission path for a complete response letter, which lists every specific deficiency the agency identified and is the alternative action at the goal date21 CFR 314.110
- 5Seek development-stage designations separately when the programme needs them, since Fast Track, Breakthrough Therapy, and Accelerated Approval each carry their own statutory criteria and request process21 U.S.C. 356(a)
Common mistakes
Treating the goal date as an approval date
FDA's action at the end of the review cycle can be a complete response letter setting out the specific deficiencies it identified, not an approval. Teams that commit manufacturing slots, launch supply, and investor guidance against the goal date absorb the cost twice when the cycle restarts.
Counting from the courier date instead of the filing decision
FDA determines within 60 days of receipt whether an application may be filed at all, and the filing date is set at 60 days after receipt. A refuse-to-file ends the plan before any priority clock matters, and models that start review on submission day never contain that branch.
Assuming Priority Review substitutes for a development-stage designation
Priority Review buys calendar at the very end. It does not buy the endpoint flexibility of Accelerated Approval or the standing that Fast Track and Breakthrough Therapy give a programme during development, and it cannot be requested mid-development to compensate for not seeking them.
When This Matters
- The BLA came back priority, so build the launch plan to a six-month goal date, not ten.
- Priority Review buys us nothing on the CMC package; the module 3 gaps still have to close before filing.
- We are holding a priority review voucher and deciding whether to spend it on this filing or sell it.
Frequently Asked Questions
Priority Review commits FDA to review and action within six months. The regulations set a 180-day timeframe for reviewing an application, and that period can be adjusted by mutual agreement or by a major amendment. FDA's filing decision itself comes within 60 days of receipt, so calendar planning should start from the filing decision.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
Sources & References
- 21 CFR 314.100 - Timeframes for reviewing applications
- 21 CFR 314.101 - Filing an application and receiving an abbreviated new drug application
- 21 CFR 314.110 - Complete response letter to the applicant
- 21 U.S.C. 360n - Priority review to encourage treatments for tropical diseases
- 21 U.S.C. 356 - Expedited approval of drugs for serious or life-threatening diseases and conditions
